PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (265)	1/21/1999 8:24:00 AM
From: NeuroInvestment	Read Replies (1) of 626

I do not believe that it is correct to assume that only this 600pt study will be US based, and that all others will be done elsewhere. There is going to be a series of Phase IIIs, in various subtypes of schizophrenia and comparing iloperidone head to head with other drugs; Risperdal, Clozaril, Zyprexa. This first is in the US, others will be as well. You are correct that Novartis is not just seeking to show advantage re: agranulocytosis, they have the larger task of matching Zyprexa, which approached $500 million in sales its first year. NeuroInvestment (www.neuroinvestment.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next